Regulatory press release 2020-08-31
Press release 2020-08-31
Regulatory press release 2020-08-21
Regulatory press release 2020-08-18
Regulatory press release 2020-08-12
Xspray’s patented method to create amorphous forms of drugs, makes it possible to enter the market long before the generic companies, with a cheaper version of the original drug. The amorphous form of Xspray’s drug renders the original company’s secondary patent, which protects certain crystalline patterns, ineffective. This creates a window over several years, where Xspray becomes sole competitor on a multi billion dollar market.
We see a large potential for development the next few years. Out technology works for most of the 54 U.S. approved protein kinase inhibitors. The process of development and commercialisation we are establishing right now, on our first product HyNap-Dasa, will be applicable for all coming product candidates. We see a growing interest from our potential partners. This is an exciting time! Per Andersson, CEO